These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

354 related items for PubMed ID: 15769863

  • 1. Inhibition of gene markers of fibrosis with a novel inhibitor of transforming growth factor-beta type I receptor kinase in puromycin-induced nephritis.
    Grygielko ET, Martin WM, Tweed C, Thornton P, Harling J, Brooks DP, Laping NJ.
    J Pharmacol Exp Ther; 2005 Jun; 313(3):943-51. PubMed ID: 15769863
    [Abstract] [Full Text] [Related]

  • 2. SB-505124 is a selective inhibitor of transforming growth factor-beta type I receptors ALK4, ALK5, and ALK7.
    DaCosta Byfield S, Major C, Laping NJ, Roberts AB.
    Mol Pharmacol; 2004 Mar; 65(3):744-52. PubMed ID: 14978253
    [Abstract] [Full Text] [Related]

  • 3. Discovery of 4-{4-[3-(pyridin-2-yl)-1H-pyrazol-4-yl]pyridin-2-yl}-N-(tetrahydro-2H- pyran-4-yl)benzamide (GW788388): a potent, selective, and orally active transforming growth factor-beta type I receptor inhibitor.
    Gellibert F, de Gouville AC, Woolven J, Mathews N, Nguyen VL, Bertho-Ruault C, Patikis A, Grygielko ET, Laping NJ, Huet S.
    J Med Chem; 2006 Apr 06; 49(7):2210-21. PubMed ID: 16570917
    [Abstract] [Full Text] [Related]

  • 4. SM16, an orally active TGF-beta type I receptor inhibitor prevents myofibroblast induction and vascular fibrosis in the rat carotid injury model.
    Fu K, Corbley MJ, Sun L, Friedman JE, Shan F, Papadatos JL, Costa D, Lutterodt F, Sweigard H, Bowes S, Choi M, Boriack-Sjodin PA, Arduini RM, Sun D, Newman MN, Zhang X, Mead JN, Chuaqui CE, Cheung HK, Zhang X, Cornebise M, Carter MB, Josiah S, Singh J, Lee WC, Gill A, Ling LE.
    Arterioscler Thromb Vasc Biol; 2008 Apr 06; 28(4):665-71. PubMed ID: 18202322
    [Abstract] [Full Text] [Related]

  • 5. IN-1130, a novel transforming growth factor-beta type I receptor kinase (ALK5) inhibitor, suppresses renal fibrosis in obstructive nephropathy.
    Moon JA, Kim HT, Cho IS, Sheen YY, Kim DK.
    Kidney Int; 2006 Oct 06; 70(7):1234-43. PubMed ID: 16929250
    [Abstract] [Full Text] [Related]

  • 6. Inhibition of activin receptor-like kinase 5 attenuates bleomycin-induced pulmonary fibrosis.
    Higashiyama H, Yoshimoto D, Kaise T, Matsubara S, Fujiwara M, Kikkawa H, Asano S, Kinoshita M.
    Exp Mol Pathol; 2007 Aug 06; 83(1):39-46. PubMed ID: 17274978
    [Abstract] [Full Text] [Related]

  • 7. Growth state-dependent regulation of plasminogen activator inhibitor type-1 gene expression during epithelial cell stimulation by serum and transforming growth factor-beta1.
    Boehm JR, Kutz SM, Sage EH, Staiano-Coico L, Higgins PJ.
    J Cell Physiol; 1999 Oct 06; 181(1):96-106. PubMed ID: 10457357
    [Abstract] [Full Text] [Related]

  • 8. Inhibition of transforming growth factor (TGF)-beta1-induced extracellular matrix with a novel inhibitor of the TGF-beta type I receptor kinase activity: SB-431542.
    Laping NJ, Grygielko E, Mathur A, Butter S, Bomberger J, Tweed C, Martin W, Fornwald J, Lehr R, Harling J, Gaster L, Callahan JF, Olson BA.
    Mol Pharmacol; 2002 Jul 06; 62(1):58-64. PubMed ID: 12065755
    [Abstract] [Full Text] [Related]

  • 9. Plasminogen activator inhibitor-I-related regulation of procollagen I (alpha1 and alpha2) by antitransforming growth factor-beta1 treatment during radiation-impaired wound healing.
    Schultze-Mosgau S, Kopp J, Thorwarth M, Rödel F, Melnychenko I, Grabenbauer GG, Amann K, Wehrhan F.
    Int J Radiat Oncol Biol Phys; 2006 Jan 01; 64(1):280-8. PubMed ID: 16377416
    [Abstract] [Full Text] [Related]

  • 10. TGF-beta 1-induced PAI-1 expression is E box/USF-dependent and requires EGFR signaling.
    Kutz SM, Higgins CE, Samarakoon R, Higgins SP, Allen RR, Qi L, Higgins PJ.
    Exp Cell Res; 2006 Apr 15; 312(7):1093-105. PubMed ID: 16457817
    [Abstract] [Full Text] [Related]

  • 11. Safflower extract: a novel renal fibrosis antagonist that functions by suppressing autocrine TGF-beta.
    Yang YL, Chang SY, Teng HC, Liu YS, Lee TC, Chuang LY, Guh JY, Chang FR, Liao TN, Huang JS, Yeh JH, Chang WT, Hung MY, Wang CJ, Chiang TA, Hung CY, Hung TJ.
    J Cell Biochem; 2008 Jun 01; 104(3):908-19. PubMed ID: 18189272
    [Abstract] [Full Text] [Related]

  • 12. Radiation and transforming growth factor-beta cooperate in transcriptional activation of the profibrotic plasminogen activator inhibitor-1 gene.
    Hageman J, Eggen BJ, Rozema T, Damman K, Kampinga HH, Coppes RP.
    Clin Cancer Res; 2005 Aug 15; 11(16):5956-64. PubMed ID: 16115939
    [Abstract] [Full Text] [Related]

  • 13. Transcriptional regulation of plasminogen activator inhibitor-1 by transforming growth factor-beta, activin A and microphthalmia-associated transcription factor.
    Murakami M, Ikeda T, Saito T, Ogawa K, Nishino Y, Nakaya K, Funaba M.
    Cell Signal; 2006 Feb 15; 18(2):256-65. PubMed ID: 15961275
    [Abstract] [Full Text] [Related]

  • 14. Fuzheng Huayu recipe and vitamin E reverse renal interstitial fibrosis through counteracting TGF-beta1-induced epithelial-to-mesenchymal transition.
    Wang QL, Yuan JL, Tao YY, Zhang Y, Liu P, Liu CH.
    J Ethnopharmacol; 2010 Feb 17; 127(3):631-40. PubMed ID: 20015471
    [Abstract] [Full Text] [Related]

  • 15. Positive feedback loop between plasminogen activator inhibitor-1 and transforming growth factor-beta1 during renal fibrosis in diabetes.
    Seo JY, Park J, Yu MR, Kim YS, Ha H, Lee HB.
    Am J Nephrol; 2009 Feb 17; 30(6):481-90. PubMed ID: 19786738
    [Abstract] [Full Text] [Related]

  • 16. SD-208, a novel transforming growth factor beta receptor I kinase inhibitor, inhibits growth and invasiveness and enhances immunogenicity of murine and human glioma cells in vitro and in vivo.
    Uhl M, Aulwurm S, Wischhusen J, Weiler M, Ma JY, Almirez R, Mangadu R, Liu YW, Platten M, Herrlinger U, Murphy A, Wong DH, Wick W, Higgins LS, Weller M.
    Cancer Res; 2004 Nov 01; 64(21):7954-61. PubMed ID: 15520202
    [Abstract] [Full Text] [Related]

  • 17. Transforming growth factor-beta type 1 receptor (ALK5) and Smad proteins mediate TIMP-1 and collagen synthesis in experimental intestinal fibrosis.
    Medina C, Santos-Martinez MJ, Santana A, Paz-Cabrera MC, Johnston MJ, Mourelle M, Salas A, Guarner F.
    J Pathol; 2011 Aug 01; 224(4):461-72. PubMed ID: 21465486
    [Abstract] [Full Text] [Related]

  • 18. Progressive transforming growth factor beta1-induced lung fibrosis is blocked by an orally active ALK5 kinase inhibitor.
    Bonniaud P, Margetts PJ, Kolb M, Schroeder JA, Kapoun AM, Damm D, Murphy A, Chakravarty S, Dugar S, Higgins L, Protter AA, Gauldie J.
    Am J Respir Crit Care Med; 2005 Apr 15; 171(8):889-98. PubMed ID: 15563636
    [Abstract] [Full Text] [Related]

  • 19. A kunitz-type protease inhibitor bikunin disrupts ligand-induced oligomerization of receptors for transforming growth factor (TGF)-beta and subsequently suppresses TGF-beta signalings.
    Yagyu T, Kobayashi H, Wakahara K, Matsuzaki H, Kondo T, Kurita N, Sekino H, Inagaki K, Suzuki M, Kanayama N, Terao T.
    FEBS Lett; 2004 Oct 22; 576(3):408-16. PubMed ID: 15498571
    [Abstract] [Full Text] [Related]

  • 20. Inhibition of TGF-beta signaling by an ALK5 inhibitor protects rats from dimethylnitrosamine-induced liver fibrosis.
    de Gouville AC, Boullay V, Krysa G, Pilot J, Brusq JM, Loriolle F, Gauthier JM, Papworth SA, Laroze A, Gellibert F, Huet S.
    Br J Pharmacol; 2005 May 22; 145(2):166-77. PubMed ID: 15723089
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 18.